Omri Amirav-Drory
General Partner @ NFX
San Francisco Bay Area, United States
Omri Amirav-Drory is a seed investor at NFX in San Francisco Bay Area focused on Biotechnology and Medical. Omri Amirav-Drory is the Founder and CEO of Renewal Bio. He previously worked at Genome Compiler as a Founder and CEO. Omri Amirav-Drory attended Stanford University.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 82%
Last updated:
For AI agents: llms.txt
Industries Omri Amirav-Drory invests in
Stages Omri Amirav-Drory invests in
Countries Omri Amirav-Drory invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 10 (59%)
- Medical 4 (24%)
- Health Care 4 (24%)
- Therapeutics 4 (24%)
- Pharmaceutical 2 (12%)
Stage
- Seed 12 (71%)
- Series A 3 (18%)
Country
- United States 8 (47%)
- Israel 3 (18%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| TwoStep Therapeutics is developing novel tumor-targeting therapeutics for solid tumors. | $62.5M / Series A / Sep 09, 2026 | ||
| Portal is a cell engineering platform firm that enables next generation cell engineering and cell analytics in research and clinical settings. | $9M / Seed / Jun 18, 2026 | ||
| Pumpkinseed allows for high-speed readings of biological bits. | $20M / Series A / May 05, 2026 | ||
| Centivax is a healthcare-based agency that provides biotechnology, pharmaceutical, medical device manufacturing, and therapeutic services. | $45M / Series A / Jul 08, 2025 | ||
| ZipBio develops next-gen gene therapies using machine learning, protein engineering, and molecular materials. | $4M / Seed / Sep 05, 2024 | ||
| TwoStep Therapeutics is developing novel tumor-targeting therapeutics for solid tumors. | $6.5M / Seed / Jun 25, 2024 | ||
| Radar Therapeutics pioneer in treatment modality, precision-expressed mRNA-based therapeutics. | $13.4M / Seed / May 23, 2024 | ||
| Transomics drug discovery platform | $6.5M / Seed / Nov 30, 2023 | ||
| Mana.bio develops artificial intelligence–based platforms for drug delivery using lipid nanoparticles (LNPs). The company combines machine learning with nanotechnology to design, test, and refine LNP formulations through computational modeling and laboratory validation. Its technology focuses on extrahepatic tissue targeting and includes researchon lung-targeted delivery and safety improvements through predictive modeling. Mana.bio has introduced ChatLNP, a tool that supports literature analysis, property prediction, and formulation optimization. The platform integrates experimental results with public data to enhance model accuracy and broaden its design capabilities for gene therapy and RNA-based medicines. | $19.5M / Seed / Oct 10, 2023 | ||
| Pangea Biomed combines ML and RNA-sequencing to offer personalized cancer treatment. | $5M / Seed / Dec 15, 2022 | ||
| See all 17 investments → | |||
Co-Investors
About NFX
NFX operates as a pre-seed & seed stage investor that is transforming how true innovators are funded for entrepreneurs. They believe that creating something of true significance starts with seeing things others do not. As Founders, they reinvented industries with this mindset. As investors, their approach is no different. They do this by askingourselves one question - ideally, how should the startup experience work for Founders, both NFX and the whole ecosystem.NFX lens is always through the eyes of the Founder. The firm approach is to first build an early-stage experience for all Founders that is powered by more software. Second, to bring the founders they back exponential yet little-known techniques for network effects and growth. Third, to make visible the typically seen methods of technology's most impactful companies.Having built 10 companies with more than $10 billion in exits across multiple industries and geographies, they're entrepreneurs first because they're entrepreneurs first. And they are determined to guard the backs of the next generation of fearless founders.
NFX Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Anna Piñol Mediano
Principal
|
|||
Pete Flint
General Partner
|
|||
Amy Lin
Chief Product Officer
|
|||
|
Anastasia Budinskaya
Investor
|
|||
Dhaval Chadha
NFX Guild Member
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Omri Amirav-Drory invest in?
Omri Amirav-Drory invests primarily in Biotechnology, Medical and Health Care startups, most often at Seed and Series A stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Omri Amirav-Drory?
Public channels for Omri Amirav-Drory include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Omri Amirav-Drory last invest?
The most recent investment recorded for Omri Amirav-Drory closed in Sep 2026. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
